Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Nuwellis Q3 operating loss narrows on margin gains, lower expenses

By Reuters News


Overview

  • US medical technology firm's Q3 net sales were flat yr/yr, impacted by prior-year backorder fulfillment

  • Q3 operating loss narrowed 24% yr/yr, driven by gross margin expansion and lower expenses

  • Pediatric segment Q3 sales rose 20% yr/yr, supporting overall business momentum


Outlook

  • Nuwellis expects expanded Aquadex indication could increase adoption if FDA clearance is obtained

  • Company says recent distribution agreements broaden product offering through existing commercial infrastructure

  • Company did not provide specific financial guidance for the current quarter or full year


Result Drivers

  • PEDIATRIC SEGMENT - Co said pediatric segment sales rose 20% yr/yr, supporting business momentum

  • GROSS MARGIN EXPANSION - Co attributed higher gross margin to increased average selling prices and benefits from contract manufacturing

  • COST MANAGEMENT - Operating expenses fell 13% yr/yr, reflecting expense management and operational efficiencies


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

$2.21 mln

Q3 Net Loss

$1.97 mln

Q3 Gross Profit

$1.54 mln

Q3 Loss from Operations

$2.05 mln


Reuters Recommended Reads

  • Nov 10 - Airway clearance device maker Electromed's Q1 revenue rises on homecare growth

  • Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows

  • Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.